HC Wainwright Reaffirms “Buy” Rating for Aprea Therapeutics (NASDAQ:APRE)

Aprea Therapeutics (NASDAQ:APRE)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a report issued on Thursday, Benzinga reports. They presently have a $20.00 price target on the stock. HC Wainwright’s target price would suggest a potential upside of 412.82% from the company’s previous close.

Separately, Wedbush reaffirmed an “outperform” rating and issued a $11.00 target price on shares of Aprea Therapeutics in a research report on Tuesday, August 13th.

Aprea Therapeutics Trading Down 6.7 %

Shares of APRE stock opened at $3.90 on Thursday. Aprea Therapeutics has a 12 month low of $2.15 and a 12 month high of $8.85. The company has a market cap of $21.18 million, a P/E ratio of -1.17 and a beta of 1.03. The firm has a fifty day moving average price of $3.25 and a 200 day moving average price of $4.11.

Aprea Therapeutics (NASDAQ:APRE) last released its quarterly earnings data on Monday, August 12th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.05. The business had revenue of $0.56 million for the quarter, compared to the consensus estimate of $0.10 million. Aprea Therapeutics had a negative return on equity of 56.38% and a negative net margin of 1,012.37%. On average, equities analysts forecast that Aprea Therapeutics will post -2.74 EPS for the current year.

Insider Activity at Aprea Therapeutics

In other news, Director Bernd R. Seizinger purchased 10,000 shares of the business’s stock in a transaction on Friday, October 11th. The shares were bought at an average price of $2.68 per share, with a total value of $26,800.00. Following the completion of the transaction, the director now directly owns 44,730 shares in the company, valued at approximately $119,876.40. This represents a 0.00 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Aprea Therapeutics news, Director Bernd R. Seizinger acquired 10,000 shares of the stock in a transaction on Friday, October 11th. The shares were bought at an average cost of $2.68 per share, with a total value of $26,800.00. Following the transaction, the director now owns 44,730 shares of the company’s stock, valued at approximately $119,876.40. This trade represents a 0.00 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Marc Duey acquired 30,000 shares of the company’s stock in a transaction on Wednesday, October 16th. The stock was acquired at an average price of $4.39 per share, for a total transaction of $131,700.00. Following the completion of the purchase, the director now owns 240,113 shares of the company’s stock, valued at $1,054,096.07. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 41,790 shares of company stock valued at $163,136 in the last three months. 12.80% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Aprea Therapeutics

An institutional investor recently bought a new position in Aprea Therapeutics stock. Dimensional Fund Advisors LP acquired a new position in shares of Aprea Therapeutics, Inc. (NASDAQ:APRE) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 11,071 shares of the company’s stock, valued at approximately $45,000. Dimensional Fund Advisors LP owned about 0.20% of Aprea Therapeutics as of its most recent filing with the SEC. Institutional investors and hedge funds own 34.19% of the company’s stock.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.